




Victor Previn joined the Board in 2001 and is one of the company’s original founders. A professional engineer with more than 30 years of experience in the ophthalmic industry, he previously served as Managing Director from 2003 to 2005 and has been Chairman since 2005. Victor is a member of the Audit and Risk Committee, the Remuneration Committee and the Nomination Committee.

Tom Spurling was CEO of Ellex Medical Lasers (ASX: ELX) from 2011 to 2019 and was appointed an Executive Director of Nova Eye Medical in 2020. He has more than 30 years of international business development experience across ophthalmic, defense and commercial markets, including complex products in highly regulated environments. He previously served as Managing Director and General Manager of Tenix LADS Corporation. Tom holds a degree in Economics and is a Chartered Accountant.

Dan Webb is based in Toronto, Canada and has more than 40 years of experience in the marketing, sale and distribution of medical devices. After 10 years in ophthalmic device sales roles, he joined the medical laser company Coherent. In 1990, he founded Coherent-AMT, now known as Clarion Medical Technologies, to import, market, sell and distribute medical devices in Canada across ophthalmic, aesthetic and surgical categories. Clarion grew to approximately $100 million in annual revenue and was sold to a multinational distribution business in 2020.

Dr Thomas Duthy PhD MBA MAICD is an execution-focused senior executive and company director with more than 22 years’ experience across Australian and international financial markets, with deep expertise in the Life Sciences and Technology sectors. He has held C-suite and Board-level roles in both ASX-listed and private company environments, including experience supporting and advising S&P/ASX Top 100/200 companies. Thomas brings a strong track record in strategic execution, corporate development, capital markets, investor relations and governance, with particular strength in advising boards and executive teams through growth initiatives, transactions, capital raisings, market-sensitive events and other complex situations requiring disciplined judgement and clear stakeholder communication.
The iTrack™ Advance has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.
INDICATIONS (International): The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open angle glaucoma.
CONTRAINDICATIONS (International): The iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle-closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal.
ADVERSE EVENTS (International): Possible adverse events with the use of the iTrack™ Advance include, but are not limited to: hyphema, elevated IOP, Descemet’s membrane detachment, shallow or flat anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.
PRECAUTIONS (International): The iTrack™ Advance should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
For full safety information, visit: https://itrack-advance.com
© 2026. Nova Eye, Inc. E&OE. Patents pending and/or granted.
iTrack™ Advance, iTrack™, ViscoInjector™ and iLumin™ are trademarks of Nova Eye,Inc.